Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOGEN INC.BIIB · Entity 1675 | Head of Pharm Ops and Tech | February 12, 2026 | February 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOGEN INC.
Report date February 12, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,611.0408 |
Reported balance
After 2026-02-12 transaction · row 1
1 source rowRow 1 · 2026-02-12 · Purchase · Acquired 3 · Balance 19,611.0408 |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2029-02-13 | Direct | 10,560 |
Reported balance
After 2026-02-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-13 · Grant · Acquired 10,560 · Balance 10,560 F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2026 Filed Feb 18, 2026 01:16 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 10,560 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000033 · form4.xml · derivative · entry 2 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,560 Underlying: Common Stock · 10,560 shares Expires 2029-02-13 F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 01:16 UTC | BIOGEN INC. BIIB · Entity 1675 | PurchaseCommon Stock | 3 | $195.04 | $585.11 |
DisclosureSEC source: 0000875045-26-000033 · form4.xml · nonDerivative · entry 1 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,611.0408 Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:03 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 4,683 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000022 · form4.xml · derivative · entry 9 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,367 Underlying: Common Stock · 4,683 shares Expires 2028-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 6, 2025. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:03 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,940 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000022 · form4.xml · derivative · entry 8 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,940 Underlying: Common Stock · 1,940 shares Expires 2027-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:03 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 2,102 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000022 · form4.xml · derivative · entry 7 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,102 shares Expires 2026-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 02/8/2023. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:03 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 1,408 | $201.18 | $283,261.44 |
DisclosureSEC source: 0000875045-26-000022 · form4.xml · nonDerivative · entry 6 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,608.0408 Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:03 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 4,683 | $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000022 · form4.xml · nonDerivative · entry 5 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,016.0408 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:03 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 914 | $201.18 | $183,878.52 |
DisclosureSEC source: 0000875045-26-000022 · form4.xml · nonDerivative · entry 4 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,333.0408 Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:03 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,940 | $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000022 · form4.xml · nonDerivative · entry 3 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,247.0408 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:03 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 1,017 | $201.18 | $204,600.06 |
DisclosureSEC source: 0000875045-26-000022 · form4.xml · nonDerivative · entry 2 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,307.0408 Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:03 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 2,102 | $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000022 · form4.xml · nonDerivative · entry 1 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,324.0408 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 166.6667 shares acquired under the Biogen Inc. employee stock purchase plan on 3/31/2025. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 22:47 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 2,272 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004461 · form4.xml · derivative · entry 3 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,272 shares Expires 2025-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 22:47 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 670 | $142.54 | $95,501.80 |
DisclosureSEC source: 0001127602-25-004461 · form4.xml · nonDerivative · entry 2 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,055.3741 Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 22:47 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 2,272 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004461 · form4.xml · nonDerivative · entry 1 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,725.3741 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 23:47 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,940 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003957 · form4.xml · derivative · entry 7 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,880 Underlying: Common Stock · 1,940 shares Expires 2027-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024. Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 23:47 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 2,102 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003957 · form4.xml · derivative · entry 6 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,102 Underlying: Common Stock · 2,102 shares Expires 2026-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 02/8/2023. Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 23:47 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 603 | $141.35 | $85,234.05 |
DisclosureSEC source: 0001127602-25-003957 · form4.xml · nonDerivative · entry 4 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,453.3741 Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 23:47 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,940 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003957 · form4.xml · nonDerivative · entry 3 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,056.3741 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 23:47 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 620 | $141.35 | $87,637.00 |
DisclosureSEC source: 0001127602-25-003957 · form4.xml · nonDerivative · entry 2 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,116.3741 Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 23:47 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 2,102 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003957 · form4.xml · nonDerivative · entry 1 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,736.3741 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2025 Filed Feb 10, 2025 23:47 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 14,050 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003957 · form4.xml · derivative · entry 5 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,050 Underlying: Common Stock · 14,050 shares Expires 2028-02-06 F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 6, 2025. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:11 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 240 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-012405 · form4.xml · derivative · entry 3 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 240 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This award was granted to the reporting person on April 1, 2021. The final portion of the awards vested on the third anniversary of the grant date. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:11 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 117 | $214.83 | $25,135.11 |
DisclosureSEC source: 0001127602-24-012405 · form4.xml · nonDerivative · entry 2 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,634.3741 Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:11 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 240 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-012405 · form4.xml · nonDerivative · entry 1 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,751.3741 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: 1. Includes 93.3846 shares acquired under the Biogen Inc. employee stock purchase plan on 3/28/2024. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:28 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 504 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-006213 · form4.xml · derivative · entry 7 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 504 shares Expires 2024-02-18 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:28 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 404 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-006213 · form4.xml · derivative · entry 6 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 504 Underlying: Common Stock · 404 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:28 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionPerformance Stock Unit · Derivative | 856 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-006213 · form4.xml · derivative · entry 5 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 856 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:28 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 196 | $219.08 | $42,939.68 |
DisclosureSEC source: 0001127602-24-006213 · form4.xml · nonDerivative · entry 4 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,417.9895 Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:28 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 404 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-006213 · form4.xml · nonDerivative · entry 3 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,613.9895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:28 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 414 | $219.08 | $90,699.12 |
DisclosureSEC source: 0001127602-24-006213 · form4.xml · nonDerivative · entry 2 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,209.9895 Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:28 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 856 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-006213 · form4.xml · nonDerivative · entry 1 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,623.9895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 23:04 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 2,272 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-004800 · form4.xml · derivative · entry 3 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,272 Underlying: Common Stock · 2,272 shares Expires 2025-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 23:04 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 761 | $240.98 | $183,385.78 |
DisclosureSEC source: 0001127602-24-004800 · form4.xml · nonDerivative · entry 2 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,767.9895 Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 23:04 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 2,272 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-004800 · form4.xml · nonDerivative · entry 1 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,528.9895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2024 Filed Feb 10, 2024 01:01 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 2,101 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-004304 · form4.xml · derivative · entry 4 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,204 Underlying: Common Stock · 2,101 shares Expires 2026-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 02/8/2023. Read SEC document |
| February 08, 2024 Filed Feb 10, 2024 01:01 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 638 | $240.30 | $153,311.40 |
DisclosureSEC source: 0001127602-24-004304 · form4.xml · nonDerivative · entry 2 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,256.9895 Read SEC document |
| February 08, 2024 Filed Feb 10, 2024 01:01 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 2,101 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-004304 · form4.xml · nonDerivative · entry 1 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,894.9895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2024 Filed Feb 10, 2024 01:01 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 5,820 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-004304 · form4.xml · derivative · entry 3 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,820 Underlying: Common Stock · 5,820 shares Expires 2027-02-07 F1 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 22:35 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantPerformance Stock Unit · Derivative | 856 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-002812 · form4.xml · derivative · entry 1 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 856 Underlying: Common Stock · 856 shares Expires 2024-02-18 F1 · shares: Represents shares earned upon satisfaction of certain performance conditions associated with performance stock units granted on February 18, 2021. The PSUs will vest on February 18, 2024. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 21:21 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 239 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-012361 · form4.xml · derivative · entry 3 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240 Underlying: Common Stock · 239 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This award was granted to the reporting person on April 1, 2021. The remaining portion of the award vests in equal installments on each of the second and third anniversary of the grant date. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 21:21 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 116 | $278.03 | $32,251.48 |
DisclosureSEC source: 0001127602-23-012361 · form4.xml · nonDerivative · entry 2 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,702.2903 Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 21:21 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 239 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-012361 · form4.xml · nonDerivative · entry 1 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,818.2903 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 91.6992 shares acquired under the Biogen Inc. employee stock purchase plan. Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 22:06 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 426 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006524 · form4.xml · derivative · entry 4 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 908 Underlying: Common Stock · 426 shares Expires 2024-02-18 F2 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 22:06 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 480 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006524 · form4.xml · derivative · entry 3 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,334 Underlying: Common Stock · 480 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 22:06 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 233 | $278.38 | $64,862.54 |
DisclosureSEC source: 0001127602-23-006524 · form4.xml · nonDerivative · entry 2 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,099.2903 Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 22:06 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 480 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006524 · form4.xml · nonDerivative · entry 1 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,579.2903 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 02:23 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 416 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005268 · form4.xml · derivative · entry 8 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 416 shares Expires 2023-02-12 F4 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F3 · derivative.exercise_date: This award was granted to the reporting person on February 12, 2020. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 02:23 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 340 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005268 · form4.xml · derivative · entry 7 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 416 Underlying: Common Stock · 340 shares Expires 2023-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This award was granted to the reporting person on February 12, 2020. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 02:23 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 2,271 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005268 · form4.xml · derivative · entry 6 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,544 Underlying: Common Stock · 2,271 shares Expires 2025-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022. Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 02:23 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 165 | $286.30 | $47,239.50 |
DisclosureSEC source: 0001127602-23-005268 · form4.xml · nonDerivative · entry 5 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,332.2903 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.